In T2DM patients with different phenotypes of chronic HF, SGLT2 inhibition with dapagiflosin over a 6-month period of administration exerted a significant positive impact on echocardiographic parameters, such as LVEF, LAVI, and E/e’ along with a decrease in serum levels of NT-proBNP in close association with an increase in serum apelin levels. This evidence concerns the gene NPPB and type 2 diabetes mellitus.